Honz Pharmaceutical Co., Ltd. Stock price

Equities

300086

CNE100000QM6

Pharmaceuticals

End-of-day quote Shenzhen S.E. 07:00:00 2024-03-26 pm EDT 5-day change 1st Jan Change
4.88 CNY -2.59% Intraday chart for Honz Pharmaceutical Co., Ltd. -7.40% -16.87%
Sales 2021 837M 116M Sales 2022 536M 74.13M Capitalization 2.8B 387M
Net income 2021 11M 1.52M Net income 2022 -188M -26.01M EV / Sales 2021 5.07 x
Net Debt 2021 334M 46.18M Net Debt 2022 313M 43.31M EV / Sales 2022 5.81 x
P/E ratio 2021
356 x
P/E ratio 2022
-14.9 x
Employees 843
Yield 2021 *
-
Yield 2022
-
Free-Float 34.57%
More Fundamentals * Assessed data
Dynamic Chart
Hainan Yougeng Investment Co., Ltd. agreed to acquire Guangdong Yuanning Pharmaceutical Co.,Ltd. from Honz Pharmaceutical Co., Ltd. for CNY12 million. CI
Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Honz Pharmaceutical Co., Ltd. cancelled the transaction announced on June 30, 2022 CI
Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Honz Pharma Optimistic Shortage of Fever Medicine Will be Solved MT
Honz Pharmaceutical Co., Ltd. Announces Directorate Appointments CI
Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Honz Pharmaceutical Co., Ltd. announced that it expects to receive CNY 297.2405 million in funding CI
Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Beijing Adds Fertility Treatment in Medical Insurance Program; Fertility Pharma Stocks Jump MT
Honz Pharmaceutical Co., Ltd. cancelled the transaction announced on November 9, 2020 CI
More news
1 day-2.59%
1 week-7.40%
Current month+0.21%
1 month-4.13%
3 months-14.69%
6 months-21.67%
Current year-16.87%
More quotes
1 week
4.88
Extreme 4.88
5.28
1 month
4.60
Extreme 4.6
5.41
Current year
3.75
Extreme 3.75
6.34
1 year
3.75
Extreme 3.75
7.20
3 years
3.75
Extreme 3.75
12.46
5 years
3.75
Extreme 3.75
12.46
10 years
3.75
Extreme 3.75
35.73
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 19-12-18
Director of Finance/CFO 47 21-09-29
Chairman 60 07-12-27
Members of the board TitleAgeSince
Director/Board Member 56 07-12-19
Chairman 60 07-12-27
Director/Board Member 55 19-12-18
More insiders
Date Price Change Volume
24-03-27 4.88 -2.59% 8,267,002
24-03-26 5.01 0.00% 6,890,515
24-03-25 5.01 -3.47% 7,392,573
24-03-22 5.19 -1.70% 10,061,300
24-03-21 5.28 +0.19% 9,102,151

End-of-day quote Shenzhen S.E., March 26, 2024

More quotes
HONZ PHARMACEUTICAL CO., LTD., formerly HAINAN HONZ PHARMACEUTICAL CO., LTD., is principally engaged in the research, development, production and distribution of drugs for children. The Company provides western medicines and Chinese patent drugs, including antipyretic and analgesic drugs, cold drugs, antibiotics drugs, respiratory system drugs, digestant and arresting convulsion drugs, as well as nutrition drugs, among others. The Company's products include nimesulide granules, cefminox sodium for injection, Zhike Juhong granules, Ganmao Qingre granules, artificial cow-bezoar and chlorphenamine maleate granules, cefaclor granules, carbocisteine granules, Jianerle granules, pediatric four vitaminsand calcium gluconate granules, as well as ribavirin pellets and Norfloxacin capsules for adults.
Calendar
More about the company
  1. Stock
  2. Equities
  3. Stock Honz Pharmaceutical Co., Ltd. - Shenzhen S.E.